NCT07049562已完成1 期
Study on the Mass Balance of [14C]HRS-8427 for Injection in Healthy Chinese Subjects
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- The percentage (%AUC) of the potent drug and its metabolites in plasma, urine and feces to the administered dose
研究概览
简要总结
To evaluate the absorption, metabolism and excretion after a single intravenous infusion of [14C]HRS-8427 in healthy Chinese subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male ages 18~45 years, inclusive;
- •The body weight should be no less than 50 kg, and the body mass index (BMI) should be within the range of 19.0 kg/m2 to 26.0 kg/m2, inclusive;
- •Subjects without sperm donation or fertility plan, and agree to adopt highly medically effective contraceptive measurements during the trial and within 3 months after the last dose;
- •Participants voluntarily sign the informed consent form before the trial, can communicate well with the researcher, have a full understanding of the trial content, process and possible adverse reactions, and can complete the trial in accordance with the protocol.
排除标准
- •A history of allergies to food, drugs allergic constitution;
- •History or presence of seriousmediacl diseases judged by the investigator as not suitable for the study;
- •Perianal diseases with regular or ongoing bloody stools, irritable bowel syndrome, and inflammatory bowel disease;
- •Habitual constipation or diarrhea;
- •Those who have undergone major surgical operations within the three months prior to screening; Or those who have undergone surgery that may affect the in vivo process or safety evaluation of the studied drug; Or those who plan to undergo surgical operations during the research period;
- •With abnormal and clinically significant comprehensive physical examinations, vital signs, or laboratory examinations
- •Abnormal 12-lead electrocardiogram and determined by the researcher as unsuitable to participate in this study
- •Tested positive for HIV antibodies, hepatitis B surface antigen, hepatitis C, or Treponema pallidum antibodies;
- •Those who have used other clinical trial drugs within 3 months before the trial or plan to participate in other clinical trials during this study period;
- •Those have experienced blood loss or donated up to 300 mL of blood, or have received blood transfusion or used blood products, or plan to donate blood during the trial or within 1 month after the end of the trial;
- •Abuse of alcohol or drugs
- •Heavy smokers or caffeine addicts.
- •Those engaged in long-term exposure to radioactive conditions; Or those who have had significant radioactive exposure within one year before the test or have participated in radiopharmaceutical tests within one year;
- •Those who cannot accept a uniform diet or have special dietary requirements;
- •Participants who may be unable to complete this study for other reasons or who the researcher deems should not be included.
研究组 & 干预措施
Treatment group A: [14C] HRS-8427
Experimental
干预措施: HRS-8427 (Drug)
结局指标
主要结局
The percentage (%AUC) of the potent drug and its metabolites in plasma, urine and feces to the administered dose
时间窗: 0~120hours
Cmax
时间窗: 0~48hours
MRT
时间窗: 0~48hours
AUC
时间窗: 0~48hours
The total radioactive recovery rate and cumulative total radioactive recovery rate at each time interval in excreta (urine and feces)
时间窗: 0~120hours
Tmax
时间窗: 0~48hours
t1/2
时间窗: 0~48hours
次要结局
- Cmax(0~48hours)
- AUC(0~48hours)
- Tmax(0~48hours)
- Adverse events(0~120hours)
- t1/2(0~48hours)
- MRT(0~48hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male ParticipantsHeart Decompensation, AcuteNCT03210909Bristol-Myers Squibb5
已完成
1 期
Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741Healthy Male VolunteersNCT00817544Orion Corporation, Orion Pharma6
尚未招募
1 期
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy SubjectsHealthy Adult SubjectNCT06576401Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.10
已完成
1 期
Mass Balance and Metabolism Study of 14C-Z-215Healthy Male SubjectsNCT02618629Zeria Pharmaceutical6
已完成
1 期
Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male VolunteersHealthyNCT02597998Boehringer Ingelheim6